Horton hears a promotion at Nile
This article was originally published in Scrip
Dr Darlene Horton, who was recently appointed CMO at Nile Therapeutics (scripintelligence.com, 2 July 2012), has been promoted to president and CEO and a director of the company. Dr Horton previously served as CMO at Itero, a company she co-founded. Joshua Kazam, who has served as Nile's president and CEO on a part-time basis since June 2009, agreed to resign upon Dr Horton's appointment. He will continue to serve on the company's board of directors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.